Exchange Traded Concepts LLC Has $175,000 Stake in Replimune Group, Inc. (NASDAQ:REPL)

Exchange Traded Concepts LLC decreased its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 34.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,010 shares of the company’s stock after selling 8,574 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Replimune Group were worth $175,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Goldman Sachs Group Inc. lifted its holdings in Replimune Group by 300.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,238,883 shares of the company’s stock worth $18,874,000 after buying an additional 1,679,553 shares during the period. Fisher Asset Management LLC lifted its stake in shares of Replimune Group by 37.7% in the fourth quarter. Fisher Asset Management LLC now owns 77,663 shares of the company’s stock valued at $655,000 after buying an additional 21,267 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in Replimune Group by 83.4% in the 1st quarter. Los Angeles Capital Management LLC now owns 66,405 shares of the company’s stock valued at $543,000 after acquiring an additional 30,203 shares in the last quarter. Diversified Trust Co bought a new position in shares of Replimune Group in the first quarter valued at approximately $94,000. Finally, Denali Advisors LLC bought a new position in Replimune Group during the 1st quarter valued at $297,000. 92.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Roth Mkm assumed coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a report on Monday, September 16th. JPMorgan Chase & Co. raised their target price on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. Finally, Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $16.80.

Replimune Group Stock Performance

NASDAQ REPL opened at $11.35 on Tuesday. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $15.18. The company has a fifty day moving average of $10.81 and a 200-day moving average of $8.89. The company has a market capitalization of $697.06 million, a P/E ratio of -3.50 and a beta of 1.21. The company has a debt-to-equity ratio of 0.16, a quick ratio of 13.46 and a current ratio of 13.46.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. As a group, equities research analysts predict that Replimune Group, Inc. will post -3.11 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the transaction, the chief financial officer now directly owns 101,057 shares in the company, valued at $1,028,760.26. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 20.60% of the stock is currently owned by insiders.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.